<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>11</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>11</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The Inhibition Effect of Triptolide on Human Endometrial Carcinoma Cell Line HEC-1B: a in vitro and in vivo Studies</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4571</FirstPage>
			<LastPage>4576</LastPage>
			<ELocationID EIdType="pii">31126</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; To investigate the inhibitory effect and the underlying mechanism of triptolide on culturedhuman endometrial carcinoma HEC-1B cells and corresponding xenograft. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: For in vitrostudies, the inhibition effect of proliferation on HEC-1B cell by triptolide was determined by MTT assay; cellcycle and apoptosis of the triptolide-treated and untreated cells were detected by flow cytometry. For in vivostudies, a xenograft tumor model of human endometrial carcinoma was established using HEC-1B cells, thenthe tumor-bearing mice were treated with high, medium, and low-dose (8 μg, 4 μg and 2 μg/day) triptolide orcisplatin at 40 μg/day or normal saline as control. The mice were treated for 10-15 days, during which body weightof the mice and volume of the xenograft were weighted. Then expression of Bcl-2 and vascular endothelial growthfactor (VEGF) was analyzed by SABC immunohistochemistry. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: Cell growth was significantly inhibitedby triptolide as observed by an inverted phase contrast microscope; the results of MTT assay indicated thattriptolide inhibits HEC-1B cell proliferation in a dose and time-dependent manner; flow cytometry showed thatlow concentration (5 ng/ml) of triptolide induces cell cycle arrest of HEC-1B cells mainly at S phase, while higherconcentration (40 or 80 ng/ml) induced cell cycle arrest of HEC-1B cells mainly at G2/M phase, and apoptosisof the cells was also induced. High-dose triptolide showed a similar tumor-inhibitory effect as cisplatin (-50%);high-dose triptolide significantly inhibited Bcl-2 and VEGF expression in the xenograft model compared tonormal saline control (P&lt;0.05). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: triptolide inhibits HEC-1B cell growth both in vitro and in mousexenograft model. Cell cycle of the tumor cells was arrested at S and G2/M phase, and the mechanism may involveinduction of tumor cell apoptosis and inhibition of tumor angiogenesis.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Uterine cancer-triptolide-VEGF- Bcl-2</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31126_d80e212efa6e6608103f990aea017a16.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
